Moderna, Inc. (MRNA) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-20

How it makes money

It generates $1.9 billion primarily from mRNA COVID vaccines, transitioning to a commercial model led by mNEXSPIKE in the U.S. retail channel.

Profitability is driven by its mRNA platform, which acts as the "software of life" to instruct cells to produce therapeutic proteins. While 2025 revenue was largely derived from Spikevax and mNEXSPIKE, the company is diversifying into RSV vaccines with mRESVIA.

Revenue outcomes are highly sensitive to public health recommendations from bodies like the ACIP, which determine the target populations and vaccination schedules that drive demand in private and retail markets.

What protects it: the moat

It maintains an advantage through a global manufacturing network and the Marlborough facility, which was purpose-built for individualized mRNA cancer therapies.

The company protects its market position by building specialized infrastructure that is difficult for rivals to replicate, such as local manufacturing sites in the UK, Canada, and Australia. These facilities ensure sovereign access to mRNA technology.

Its individualized neoantigen therapy, developed in collaboration with Merck, relies on a proprietary process that demonstrated sustained survival improvement in Phase 2b clinical trials for high-risk melanoma patients.

What growth costs

It is spending to onshore drug manufacturing to Norwood by 2027 and advancing 35 clinical programs supported by a $1.5 billion credit facility.

Growth requires heavy investment in clinical trials and infrastructure. The company is currently expanding its U.S. manufacturing capabilities to enable end-to-end production of mRNA vaccines and therapeutics by 2027.

To sustain this pipeline, which includes 25 candidates in clinical studies, it secured a five-year loan facility. This capital supports the high costs of trials in oncology and rare diseases as the company works toward a cash breakeven goal.

What could damage it

A competitor's contract with the European Commission excludes it from selling COVID vaccines in multiple European markets until the end of 2026.

The business faces structural impairment if it cannot break into markets dominated by larger rivals like Pfizer and GSK. These competitors use their scale to bundle products and secure exclusive long-term contracts, effectively locking the company out of entire geographic regions.

Furthermore, if regulatory guidance from agencies like the FDA or CDC narrows the eligible patient population for vaccines, it could result in demand falling significantly below the levels required to sustain its manufacturing infrastructure.

About Moderna, Inc.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Other companies in Biotechnology